Purchase Order W81K0216P0301
- Not listed
- This federal contract award was issued by the Department of Veterans Affairs Veterans Health Administration to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, a provider of genomic testing services and COVID-19 testing kits and services to U.S. federal government agencies. The contract is for germline genetic testing with a potential value of $150,000.00 and is a Firm Fixed Price BPA Call order. Fulgent Therapeutics holds a separate $950,000.00 Blanket Purchase Agreement from...
- The Department of Veterans Affairs Veterans Health Administration awarded Fulgent Therapeutics LLC a $3.2 million firm fixed price delivery order against its Medical Laboratory Testing and Analysis Services GSA Schedule contract. Fulgent Therapeutics, doing business as Fulgent Diagnostics and a division of Fulgent Genetics, will provide COVID-19 cost per test services to VHA's Veterans Integrated Service Network 21 through December 2020. The contract supports VHA's coronavirus disease testing...
- The Department of Veterans Affairs Strategic Acquisition Center Frederick awarded a $2.949 million delivery order for germline pharmacogenomic molecular testing to Fulgent Therapeutics LLC (doing business as Fulgent Diagnostics) on September 30, 2024. This supplemental agreement represents work within scope and is issued without a set-aside designation, indicating open competition. The work will be performed in Frederick, Maryland, with an ultimate completion date of September 29, 2029. This...
- This is a firm fixed price purchase order awarded by the Department of Veterans Affairs (VA) to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, a subsidiary of Fulgent Genetics, Inc. The contract is for the delivery of laboratory testing kits, with a ceiling value of $889,097.43 and a period of performance through December 30, 2024. There was no set-aside designation used for this award. Fulgent Diagnostics is a provider of genomic testing services and COVID-19 testing kits...
- Veterans Integrated Service Network 17 awarded a $1,003,754 definitive contract to Fulgent Therapeutics LLC (doing business as Fulgent Diagnostics) for genetics testing on October 1, 2024, under firm fixed-price pricing with no set-aside. Place of performance is El Monte, California. The contract carries an ultimate completion date of September 30, 2029. The originating solicitation addresses genetics testing under Executive Order 14398, supporting the Veterans Affairs healthcare mission.
- The Department of Veterans Affairs, through the VA Strategic Acquisition Center Frederick, issued a delivery order to Fulgent Therapeutics LLC on September 30, 2025, with a ceiling value of $6,573,600 for germline genetic testing services supporting the Veterans Health Administration National Oncology Program. This is a Year 2 within-scope modification under the Germline PGx Services indefinite delivery vehicle. The order is priced on a firm fixed price basis with an ultimate completion date...
- <p>The Department of Veterans Affairs, Veterans Integrated Service Network 20, awarded a purchase order to Fulgent Genetics, Inc. for genetic testing services supporting the VA Portland Health Care System, with a ceiling value of $331,400.00 and an award date of August 1, 2024.</p> <p>Performance will be executed in Portland, Oregon 97239. The order is priced on a firm fixed-price basis with an ultimate completion date of July 31, 2027. No small business set-aside was applied.</p>
- The Department of the Army Medical Command awarded a $13,815.84 firm fixed price call against the Medical Laboratory Testing and Analysis Services Federal Supply Schedule to Genomic Health, Inc., a subsidiary of Exact Sciences Corporation, for cancer testing referral laboratory services. The contract has a completion date of January 31, 2021 and was awarded on August 31, 2020. Performance will take place at Fort Liberty, North Carolina. No set-aside designation was used for this award placed...
- This is a $100,000 firm-fixed price purchase order contract awarded by the U.S. Army Medical Command (MEDCOM) to Gen-Probe Incorporated, a medical diagnostics company specializing in molecular diagnostic testing systems and assays. The contract is for the delivery of NAAT (Nucleic Acid Amplification Testing) reagents and equipment to support testing at the Womack Army Medical Center in Fort Bragg, North Carolina. The original solicitation was a sole-source procurement issued as a combined...
- This federal contract award to Prevention Genetics LLC, doing business as Prevention Genetics, is for germline genetic testing services to support the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 19 in Salt Lake City, Utah. The single-award Blanket Purchase Agreement (BPA) is valued at $6,942,060 and runs from September 2021 through September 2024, allowing the VA to issue multiple task orders for genetic testing. Prevention Genetics, a for-profit limited...
This federal contract award to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, is a $935,715 firm fixed price purchase order for NEXT GEN TESTING AT MAMC, awarded by the U.S. Army Medical Command. The contract has a period of performance through September 30, 2019 and does not have a set-aside designation. Fulgent Therapeutics is a subsidiary of Fulgent Genetics, Inc., a provider of comprehensive genomic testing services to various federal agencies including the Department of Veterans Affairs, Department of Health and Human Services, and Centers for Disease Control and Prevention. The contract covers next generation sequencing and genetic testing services to be provided at Tripler Army Medical Center. Fulgent Therapeutics holds a $950,000 blanket purchase agreement with the Army Medical Command to provide these services through September 2025.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
Nexty Generation Testing at Madigan AMC | W81K0216T0130 | Department of the Army Medical Command | Award Notice 2/2 | 8/9/16, 5:08 PM | |
Next Generation Genetic Testing | W81K02-16-T-0130 | Department of the Army Medical Command | Award Notice 1/2 | 6/1/16, 5:45 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00003 | Terminate for Convenience | ($56k) | 3/9/22 | |
| P00002 | Terminate for Convenience | ($200k) | 2/13/18 | |
| P00001 | Other Administrative Action | $397.5k | 10/26/16 | |
| Not listed | Not listed | $0 | 9/19/16 |